Skip to content

An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Hepatitis B | Liver Diseases | Hepatitis

The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical questions regarding the management of CHB by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to antiviral treatments used in clinical practice.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion

1. Male or female patients, age ≥18 years
2. Being managed for chronic hepatitis B (CHB), including patients who have achieved functional cure and patients with concurrent delta hepatitis

Exclusion

1. Inability to provide written informed consent
2. Known history of Human Immunodeficiency Virus (HIV)
3. History of liver transplantation

Study Location

UHN Toronto General Hospital
UHN Toronto General Hospital
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

David KH Wong, MD

[email protected]
416-340-3279
Study Sponsored By
Target PharmaSolutions, Inc.
Participants Required
More Information
Study ID: NCT03692897